Neurology

Patients with multiple sclerosis showed more advanced white matter alteration compared to those with neuromyelitis optica spectrum disorder, although both exhibited altered network topologies. Along with neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS) is one of the major chronic inflammatory demyelinating disorders that can affect the central nervous system. This study, published in the...

This analysis of patients with NMOSD provides data about how functional connectivity in specific cognitive networks impacts cognitive impairment symptoms. Neuromyelitis optica spectrum disorder (NMOSD) can manifest a variety of symptoms, some being more uncommon than others. Cognitive impairment is one of the common symptoms among patients with this disorder, but the mechanism by which...

MS is a chronic inflammatory disease of the CNS, the pathogenesis associated with miRNAs, which also serve as effective therapeutic targets in MS patients. Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system (CNS). MicroRNAs (miRNAs) are complex endogenous biomolecules that function as gene super-regulators. This review was published in...

Cognitive rehabilitation interventions for multiple sclerosis (MS) patients include psychoeducational feedback, restorative, and compensatory interventions. GPs can assist their MS patients by helping them understand the benefits of cognitive rehabilitation and by facilitating access to services. Cognitive rehabilitation refers to the alleviation of cognitive deficits associated with neurological insults. This is a person-centered approach to...

MS is a chronic inflammatory disease of the CNS, the pathogenesis associated with miRNAs. miRNAs also serve as effective therapeutic targets in MS patients. Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system (CNS). MicroRNAs (miRNAs) are complex endogenous biomolecules that function as gene super-regulators. This review was published in...

Patients with MS demonstrate an accumulation of disabilities, which can be delayed by applying disease-modifying therapies. Multiple sclerosis (MS) patients acquire disability via progression independent of relapse activity (PIRA) or relapse-associated worsening (RAW). This study was published in the journal BRAIN, and discusses the contribution of MS relapses to the worsening of disability through the...

A recent clinical trial indicates that self-acupressure is an effective non-pharmaceutical treatment for reducing fatigue in multiple sclerosis patients. Multiple Sclerosis (MS) is a neurological illness that causes inflammation, neurological impairment, and neurodegeneration in the central nervous system. The disorder may potentially cause irreparable damage to the nerves. One of the major symptoms of MS...

Socioeconomic disadvantage may be a potential risk factor for poor clinical outcomes in patients with multiple sclerosis (MS). A retrospective analysis was conducted to assess this association and open the discussion for possible solutions. Patients with multiple sclerosis (MS) who are at a socioeconomic disadvantage may bear a high burden of disease and worse outcomes....

The prevalence of multiple sclerosis (MS) in minority populations is not well documented or understood. A retrospective cohort analysis evaluated the prevalence of MS with data gathered from a Florida database and provided insight into the prevalence and care of MS. Nearly one million people live with multiple sclerosis (MS) in the United States. However,...